SpringWorks Therapeutics had its Relative Strength (RS) Rating upgraded from 88 to 91 Friday.
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks tend to have an 80 or higher RS Rating as they begin their biggest runs.
How To Use Stock Charts To Stay Profitable And Protected
SpringWorks Therapeutics broke out earlier, but is now trading around 3% below the prior 53.92 entry from a consolidation. If a stock you're tracking clears a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new consolidation and breakout. Also understand that the latest consolidation is a later-stage base, and such bases are more prone to failure.
SpringWorks Therapeutics reported 0% earnings growth in its most recent report. Sales increased 1,029%.
SpringWorks Therapeutics holds the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
